EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer—2020 update. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, RCN van den Bergh, E Briers… - European urology, 2021 - Elsevier
Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …
Risks from deferring treatment for genitourinary cancers: a collaborative review to aid triage and management during the COVID-19 pandemic
Context The coronavirus disease 2019 (COVID-19) pandemic is leading to delays in the
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
treatment of many urologic cancers. Objective To provide a contemporary picture of the risks …
Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management
JA Eastham, GB Auffenberg, DA Barocas… - The Journal of …, 2022 - auajournals.org
Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …
Control of the activity of CAR-T cells within tumours via focused ultrasound
Focused ultrasound can deliver energy safely and non-invasively into tissues at depths of
centimetres. Here we show that the genetics and cellular functions of chimeric antigen …
centimetres. Here we show that the genetics and cellular functions of chimeric antigen …
Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort
Background Active surveillance (AS) is the preferred management option for most men with
grade group (GG) 1 prostate cancer (PCa). Questions persist regarding long-term outcomes …
grade group (GG) 1 prostate cancer (PCa). Questions persist regarding long-term outcomes …
Defining clinically significant prostate cancer on the basis of pathological findings
A Matoso, JI Epstein - Histopathology, 2019 - Wiley Online Library
The definition of clinically significant prostate cancer is a dynamic process that was initiated
many decades ago, when there was already evidence that a great proportion of patients with …
many decades ago, when there was already evidence that a great proportion of patients with …
Active surveillance for low-risk prostate cancer: the European Association of Urology position in 2018
Active surveillance (AS) represents a well-recognized management option for many patients
with low-and very low-risk prostate cancer (PCa). AS aims to reduce overtreatment whilst …
with low-and very low-risk prostate cancer (PCa). AS aims to reduce overtreatment whilst …
Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression
Context Active surveillance (AS) is increasingly selected among patients with localized,
intermediate-risk (IR) prostate cancer (PCa). However, the safety and optimal candidate …
intermediate-risk (IR) prostate cancer (PCa). However, the safety and optimal candidate …
Active surveillance in intermediate‐risk prostate cancer
L Klotz - BJU international, 2020 - Wiley Online Library
Objectives Active surveillance (AS), now the standard of care for most men with favourable‐
risk prostate cancer, is appealing for selected men with 'favourable'intermediate‐risk …
risk prostate cancer, is appealing for selected men with 'favourable'intermediate‐risk …
Proteomic discovery of non-invasive biomarkers of localized prostate cancer using mass spectrometry
Prostate cancer is the second most frequently diagnosed non-skin cancer in men worldwide.
Patient outcomes are remarkably heterogeneous and the best existing clinical prognostic …
Patient outcomes are remarkably heterogeneous and the best existing clinical prognostic …